AFMD News and Press, Affimed N.V. From 12/08/21

HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the initiation of patient recruitment for the open-label, multi-center phase 1/...

Biopharmaceutical stocks are slated to end the year on a sour note. Apart from top COVID-19 vaccine players like Pfizer , Moderna , and Novavax , investors have shown little to no interest in owning these growth-oriented equities in 2021. As proof, the SPDR S&P Biotech ETF...

Shares of the German cancer immunotherapy company Affimed (NASDAQ: AFMD) jumped by as much as 25% in premarket trading Monday morning. The biotech's stock is popping in early morning action today in response to overwhelmingly positive early-stage trial results for its lead product c...

Astra Space (NASDAQ:ASTR) +35% after successful commercial orbital launch iSpecimen (NASDAQ:ISPC) +26% selected by U.S. Government and private researchers to supply critical human biospecimens for advanced phase of COVID-19 research PainReform (NASDAQ:PRFX) +19%. Vonage Holding...

Affimed (NASDAQ:AFMD) soars 21.6% premarket after announcing interim clinical results from Phase 1-2 study, evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed’s innate cell engager (NYSE:ICE) AFM13. As of October 31, 2021, a total of 18 patie...

100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1 st of 2 planned cycles at the recommended phase 2 dose of 10 8 cord blood-derived natural killer (cbNK) cells/kg pre-complexed with AF...

Shares in Affirmed (NASDAQ: AFMD) , a clinical-stage, immune-oncology company, rose more than 12% on Wednesday. The stock closed at $6.12 on Tuesday, then opened at $6.22 on Wednesday, and reached $7 in the early afternoon. Over the past 52 weeks, the low for Affirmed stock was $4.4...

GT Biopharma is an early-stage oncology company with one clinical asset. GT Biopharma will likely shift focus to their 2nd generation therapies, which are still preclinical. Lack of meaningful positive catalysts in the next year reduces attractiveness of investment. For furt...

HEIDELBERG, Germany, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three posters with preclinical data of its innate cell engagers (ICE®...

Image source: The Motley Fool. Affimed NV (NASDAQ: AFMD) Q3 2021 Earnings Call Nov 10, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Affimed NV (AFMD) Q3 2021 Earnings Call Transcript